Abstract:Recombinant adeno-associated virus (rAAV) vectors possess the unique ability to introduce genetic alterations at sites of homology in genomic DNA through a mechanism thought to predominantly involve homologous recombination. We have investigated the efficiency of this approach using a mutant enhanced green fluorescent protein (eGFP) fluorescence recovery assay that facilitates detection of gene correction events in living cells under nonselective conditions. Our data demonstrate that rAAV infection can correct a mutant eGFP transgene at an efficiency of 0.1% in 293 cells, as determined by fluorescence-activated cell-sorting analysis. Gene repair was also confirmed using clonal expansion of GFP-positive cells and sequencing of the eGFP transgene. These results support previous findings demonstrating the efficacy of rAAV for gene targeting. In an effort to improve gene-targeting efficiencies, we evaluated several agents known to increase rAAV transduction (i.e., expression of an expressed gene), including genotoxic stress and proteasome inhibitors, but observed no correlation between the level of gene repair and rAAV transduction. Interestingly, however, our results demonstrated that enrichment of G(1)/S-phase cells in the target population through the addition of thymidine moderately (similar to2-fold) increased gene correction compared to cells in other cell cycle phases, including G(0)/G1,G(1), and G(2)/M. These results suggest that the S phase of the cell cycle may more efficiently facilitate gene repair by rAAV. Transgenic mice expressing the mutant GFP were used to evaluate rAAV targeting efficiencies in primary fetal fibroblast and tibialis muscles. However, targeting efficiencies in primary mouse fetal fibroblasts were significantly lower (similar to0.006%) than in 293 cells, and no correction was seen in tibialis muscles following rAAV infection. To evaluate the molecular structures of rAAV genomes that might be responsible for gene repair, single-cell injection studies were performed with purified viral DNA in a mutant eGFP target cell line. However, the failure of direct cytoplasm- or nucleus -injected rAAV DNA to facilitate gene repair suggests that some aspect of intracellular viral processing may be required to prime recombinant viral genomes for gene repair events.

The Role of Recombinant AAV in Precise Genome Editing

AAV-mediated gene therapies by miniature gene editing tools

Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo

Precision genome editing using combinatorial viral vector delivery of CRISPR-Cas9 nucleases and donor DNA constructs

In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease

AAV-mediated in vivo genome editing in vascular endothelial cells.

Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor

AAV-mediated genome editing is influenced by the formation of R-loops

High levels of AAV vector integration into CRISPR-induced DNA breaks

Efficient in Vivo Base Editing Via Single Adeno-Associated Viruses with Size-Optimized Genomes Encoding Compact Adenine Base Editors

Generation of targeted adeno-associated virus (AAV) vectors for human gene therapy.

Delivery of CRISPR/Cas9 system by AAV as vectors for gene therapy

Optimization strategies and advances in the research and development of AAV‐based gene therapy to deliver large transgenes

Development Of Highly Efficient Dual-Aav Split Adenosine Base Editor For In Vivo Gene Therapy

AAV- based vector improvements unrelated to capsid protein modification

A concept of eliminating nonhomologous recombination for scalable and safe AAV vector generation for human gene therapy.

Targeted correction of single-base-pair mutations with adeno-associated virus vectors under nonselective conditions.

Adeno-associated virus as a delivery vector for gene therapy of human diseases

AAV-Based Targeting Gene Therapy

AAV vector-derived elements integrate into Cas9-generated double-strand breaks and disrupt gene transcription

Adeno-associated virus vector as a platform for gene therapy delivery